[1] Bustin SA, Nolan T. RT-qPCR testing of SARS-CoV-2: a primer. Int J Mol Sci, 2020; 21, 3004.
[2] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020; 382, 1708−20. doi:  10.1056/NEJMoa2002032
[3] Zhao JJ, Yuan Q, Wang HY, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis, 2020; 71, 2027−34. doi:  10.1093/cid/ciaa344
[4] Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet, 2020; 396, 535−44. doi:  10.1016/S0140-6736(20)31483-5
[5] Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun, 2020; 11, 3500. doi:  10.1038/s41467-020-17318-x
[6] Zhang WJ, Lv X, Huang C, et al. Clinical evaluation and application of detection of IgM and IgG antibodies against SARS-CoV-2 using a colloidal gold immunochromatography assay. Chin J Virol, 2020; 36, 348−54. (In Chinese
[7] Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol, 1978; 107, 71−6. doi:  10.1093/oxfordjournals.aje.a112510
[8] Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet, 2020; 396, 313−9.
[9] Zeng FF, Dai C, Cai PC, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol, 2020; 92, 2050−4. doi:  10.1002/jmv.25989
[10] Bao CP, Liu XH, Zhang H, et al. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol, 2020; 17, 701−9. doi:  10.1016/j.jacr.2020.03.006